Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Indolent B-Cell Non-Hodgkin Lymphoma: early-phase trial registry

3 of 7 indexed Indolent B-Cell Non-Hodgkin Lymphoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Indolent B-Cell Non-Hodgkin Lymphoma: 7 US clinical trials tracked, 3 recruiting.

Indolent B-Cell Non-Hodgkin Lymphoma is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Synthekine, running 1 of these trials.

Enrollment posture brief

Registry condition indolent-b-cell-non-hodgkin-lymphoma

OPEN 3 | RECR 43% | LATE 0 | EARLY 7 | RANK #2497 | SPON 1

Volume-matched condition peers

Nearest open-share peer: Adrenoleukodystrophy (43% recruiting · 7 trials)

ACL Tear71.4%ACL57.1%Indolent B-Cell Non-Hodg (th…43%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Indolent B-Cell Non-Hodgkin Lymphoma

Indolent B-Cell Non-Hodgkin Lymphoma lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Indolent B-Cell Non-Hodgkin Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Indolent B-Cell Non-Hodgkin Lymphoma is recruiting below its size-band peers.

    3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Indolent B-Cell Non-Hodgkin Lymphoma trials is spread across many organizations.

    Synthekine accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Indolent B-Cell Non-Hodgkin Lymphoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 42 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.

  4. Indolent B-Cell Non-Hodgkin Lymphoma research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 22

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 2

Top Sponsors

Synthekine 1 trials
Verismo Therapeutics 1 trials
BioInvent International AB 1 trials
University of Nebraska 1 trials
University of Washington 1 trials
M.D. Anderson Cancer Center 1 trials
Mayo Clinic 1 trials

Named interventions

Most-linked intervention names on Indolent B-Cell Non-Hodgkin Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Rituximab Biological
2 trials
Computed Tomography Procedure
2 trials
Post-infusion radiation Radiation
1 trials
Bridging radiation therapy Radiation
1 trials
CD47 Antagonist ALX148 Drug
1 trials
STK-009 Drug
1 trials
SYNCAR-001 Drug
1 trials
Involved-site Radiation Therapy (12 Fractions) Radiation
1 trials

US sites by state

Facility locations filed on Indolent B-Cell Non-Hodgkin Lymphoma trials. A trial with sites in several states counts in each.

Georgia 2 trials
Wisconsin 1 trials
Washington 1 trials
Texas 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New York 1 trials
New Jersey 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Indolent B-Cell Non-Hodgkin Lymphoma page

7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 3 Indolent B-Cell Non-Hodgkin Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Synthekine sponsors the most Indolent B-Cell Non-Hodgkin Lymphoma trials on record, review their full trial history before evaluating a specific study. See Synthekine's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Indolent B-Cell Non-Hodgkin Lymphoma condition card totals 7 registered trials; most-linked intervention Rituximab; top US site state Georgia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.